论文部分内容阅读
目的:观察运用扶正通络法(朱氏加味定喘散)联合舒利迭吸入防治儿童哮喘的临床疗效及其对免疫功能的影响。方法:将100例哮喘患儿随机分成治疗组和对照组各50例,两组均吸入舒利迭50μg/100μg,12 h1次,治疗组同时予朱氏加味定喘散口服,两组疗程均为3个月。观察两组患儿临床疗效、治疗前后哮喘控制测试(ACT评分)、可溶性白细胞介素4(IL-4)、肿瘤坏死因子-α(TNF-α)、干扰素-γ(IFN-γ)的变化。结果:治疗组总有效率96.00%,对照组为84.00%,治疗组明显高于对照组(P<0.05)。两组治疗后ACT评分均较本组治疗前升高,TNF-α及IL-4降低(P<0.01),且治疗组优于对照组(P<0.05或P<0.01)。治疗组治疗后外周血IFN-γ较治疗前升高(P<0.01)。结论:该研究证实朱氏加味定喘散加减口服联合舒利迭吸入能改善哮喘患儿临床症状,调节免疫功能,有效防治哮喘。
Objective: To observe the clinical effect of Fuzheng Tongluo Decoction (Decoction of Decoction of Zhuzheng Jiawei Dingchuan Powder) combined with seretide inhalation in the prevention and treatment of childhood asthma and its effect on immune function. Methods: One hundred children with asthma were randomly divided into treatment group (50 cases) and control group (50 cases). Both groups were given 50 μg / 100 μg / For 3 months. The clinical efficacy, asthma control test (ACT score), soluble interleukin 4 (IL-4), tumor necrosis factor-α (TNF-α) and interferon-γ Variety. Results: The total effective rate was 96.00% in the treatment group and 84.00% in the control group, which was significantly higher in the treatment group than in the control group (P <0.05). The ACT scores of both groups were significantly higher than those before treatment (P <0.01), and the levels of TNF-α and IL-4 in treatment group were higher than those in control group (P <0.05 or P <0.01). After treatment, the level of IFN-γ in peripheral blood in treatment group was significantly higher than that before treatment (P <0.01). Conclusions: This study confirmed that Zhu’s Modified Dingchuan Powder combined with oral inhalation of seretide can improve the clinical symptoms of asthmatic children, regulate immune function, and effectively prevent and treat asthma.